Svein Mathisen, CEO of BioInvent, added: "We are pleased that we and our partner ThromboGenics have taken this innovative anti-cancer agent to the clinical stage. TB-403 could be a novel treatment of cancer. There is a clear medical need for an effective and safe new anti-angiogenic treatment of cancer. TB-403 does not induce an angiogenic switch and resistance to the drug, has potentially less side effects and may therefore be well suited for long term treatment."
ThromboGenics and BioInvent also intend to develop TB-403 for eye diseases, to block uncontrolled blood vessel growth in conditions such as age-related macular degeneration (AMD) and diabetic retinopathy.
Angiogenesis inhibitors such as TB-403 are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutriments. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. Currently available angiogenesis inhibitors specifically target vascular endothelial growth factor (VEGF), which plays an important role in promoting the formation of blood vessels. PlGF is a homologue of VEGF but, unlike other angiogenesis factors such as VEGF, it does not affect normal, physiological angiogenesis and is only involved in the angiogenesis process which takes place in the diseased tissue. Therefore, as an inhibitor of PlGF, TB-403 is likely to inhibit tumour growth without the side effects associated with other anti-angiogenic therapies.
Extensive research in this area was recently published as the featured article in the journal Cell ("Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors Without Affecting Healthy Vessels," Carmeliet, Fischer, et al, Cell 131, 463-475, November 2, 2007).
ThromboGenics is a biotechnology company focused on discovery and
development of biopharmaceuticals for the treatment
|SOURCE ThromboGenics NV|
Copyright©2008 PR Newswire.
All rights reserved